Brought to you by 
Gilead gets rights to Ono's oral BTK inhibitor
24 Jul 2019
Executive Summary
Ono Pharmaceutical Co. Ltd. granted Gilead Sciences Inc. exclusive rights to co-develop and sell ONO4059, an oral Bruton’s tyrosine kinase (BTK) inhibitor. Gilead can commercialize the compound worldwide, excluding Japan, South Korea, Taiwan, China, and the Association of Southeast Asian Nations (ASEAN), where Ono retains rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead gets rights to Ono's oral BTK inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice